Видео ютуба по тегу Asco20

ASCO20 Virtual Scientific Program Research Round Up: Head and Neck Cancer and Melanoma
ASCO20 Virtual Scientific Program Research Round Up: Head and Neck Cancer and Melanoma
ASCO20 Virtual Scientific Program Research Round Up: Leukemia, Colorectal Cancer, and Lung Cancer
ASCO20 Virtual Scientific Program Research Round Up: Leukemia, Colorectal Cancer, and Lung Cancer
ASCO20 Virtual Scientific Program Research Round Up: Breast Cancer, Sarcoma, and Supportive Care
ASCO20 Virtual Scientific Program Research Round Up: Breast Cancer, Sarcoma, and Supportive Care
ASCO20 Virtual Scientific Program Research Round Up: Central Nervous System Tumors and Lymphoma
ASCO20 Virtual Scientific Program Research Round Up: Central Nervous System Tumors and Lymphoma
ASCO20 - Nadia Harbeck, München: HER2-positiver, metastasierter Brustkrebs - die Behandlung
ASCO20 - Nadia Harbeck, München: HER2-positiver, metastasierter Brustkrebs - die Behandlung
ASCO20 - Wolfgang Janni, Ulm: Olaparib (PARP-Inhibitor), wann für wen?
ASCO20 - Wolfgang Janni, Ulm: Olaparib (PARP-Inhibitor), wann für wen?
ASCO20 Virtual: Grosser Fortschritt bei der operativen Therapie des Ovarialkarzinom
ASCO20 Virtual: Grosser Fortschritt bei der operativen Therapie des Ovarialkarzinom
ASCO20 Virtual: Zelltherapie bei HPV-assoziierten Karzinomata
ASCO20 Virtual: Zelltherapie bei HPV-assoziierten Karzinomata
ASCO20 - Volkmar Müller, Hamburg: Demenzrisiko bei antihormoneller Therapie erhöht?
ASCO20 - Volkmar Müller, Hamburg: Demenzrisiko bei antihormoneller Therapie erhöht?
ASCO20 - Volkmar Müller, Hamburg: Frühzeitige Einbeziehung der Palliativmedizin ist von Vorteil
ASCO20 - Volkmar Müller, Hamburg: Frühzeitige Einbeziehung der Palliativmedizin ist von Vorteil
ASCO20 - Christian Jackisch, Offenbach: Hormonrezeptor positiver Brustkrebs - die Behandlung
ASCO20 - Christian Jackisch, Offenbach: Hormonrezeptor positiver Brustkrebs - die Behandlung
ASCO20 Virtual: Therapie metastasiertes triple-negatives Mammakarzinom
ASCO20 Virtual: Therapie metastasiertes triple-negatives Mammakarzinom
ASCO20 Virtual: Überlebensvorteil mit PARP-Inhibitoren beim Ovarialkarzinom
ASCO20 Virtual: Überlebensvorteil mit PARP-Inhibitoren beim Ovarialkarzinom
ASCO20 Presentation
ASCO20 Presentation
#ASCO20. Dr. Răzvan Curcă, despre principalele noutăți în cancerul uroterial metastatic
#ASCO20. Dr. Răzvan Curcă, despre principalele noutăți în cancerul uroterial metastatic
TheraP Study: Lu-PSMA vs. cabazitaxel #ASCO20 #ANZUP
TheraP Study: Lu-PSMA vs. cabazitaxel #ASCO20 #ANZUP
ASCO20 Virtual Education Program Special Session: ASCO Voices
ASCO20 Virtual Education Program Special Session: ASCO Voices
Reshma Mahtani, DO | Sylvester Cancer | ASCO20 Breast Cancer Reactions: MINDACT for Early Stage
Reshma Mahtani, DO | Sylvester Cancer | ASCO20 Breast Cancer Reactions: MINDACT for Early Stage
Ruta Rao, MD | Rush University | ASCO20 Breast Cancer Reactions: MINDACT for Early Stage
Ruta Rao, MD | Rush University | ASCO20 Breast Cancer Reactions: MINDACT for Early Stage
Ranju Gupta, MD | Lehigh Valley Health | ASCO20 Breast Cancer Reactions: MINDACT for Early Stage
Ranju Gupta, MD | Lehigh Valley Health | ASCO20 Breast Cancer Reactions: MINDACT for Early Stage
Martin Dietrich, MD | FL Cancer Specialists | ASCO20 Breast Cancer Reactions: MINDACT for EarlyStage
Martin Dietrich, MD | FL Cancer Specialists | ASCO20 Breast Cancer Reactions: MINDACT for EarlyStage
Jennifer Crozier, MD | Baptist MD Anderson | ASCO20 Breast Cancer Reactions: MINDACT for Early Stage
Jennifer Crozier, MD | Baptist MD Anderson | ASCO20 Breast Cancer Reactions: MINDACT for Early Stage
ASCO20 - New Research in Non-Small Cell Lung Cancer
ASCO20 - New Research in Non-Small Cell Lung Cancer
ASCO20 - PROSPER Trial Data - Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)
ASCO20 - PROSPER Trial Data - Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)
ASCO20 - KRAS Wild-Type Pancreatic Cancer
ASCO20 - KRAS Wild-Type Pancreatic Cancer